2-(2-(3-isopropylureido)-5-(trifluoromethyl)benzamido)acetic acid | 439151-09-4

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 2-(2-(3-isopropylureido)-5-(trifluoromethyl)benzamido)acetic acid
• 英文别名: [2-(3-Isopropyl-ureido)-5 trifluoromethyl-benzoylamino]-acetic acid；2-[2-(3-isopropyl-ureido)-5-trifluoromethyl-benzoylamino]-acetic acid；2-[[2-(Propan-2-ylcarbamoylamino)-5-(trifluoromethyl)benzoyl]amino]acetic acid
• CAS: 439151-09-4
• 化学式: C₁₄H₁₆F₃N₃O₄
• 分子量: 347.294
• InChiKey: CDGNAFMJEFZWCB-UHFFFAOYSA-N

物化性质

• 沸点：
  467.1±45.0 °C(Predicted)
• 密度：
  1.390±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2
• 重原子数：
  24
• 可旋转键数：
  5
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.36
• 拓扑面积：
  108
• 氢给体数：
  4
• 氢受体数：
  7

反应信息

• 作为反应物：
  描述：

  2-(2-(3-isopropylureido)-5-(trifluoromethyl)benzamido)acetic acid 、 N,N-二异丙基乙胺 在 三氟乙酸 、 N-[(dimethylamino)-3-oxo-1H-1,2,3-triazolo[4,5-b]pyridin-1-yl-methylene]-N-methylmethanaminium hexafluorophosphate 作用下， 以 二氯甲烷 为溶剂， 生成 (+/-)N-{2-[((1S*,2R*)-2-{[(4-bromophenyl)thio]methyl}cyclohexyl)amino]-2-oxoethyl}-2-{[(isopropylamino)carbonyl]amino}-5-(trifluoromethyl)benzamide
  参考文献：
  名称：

  Cyclic derivatives as modulators of chemokine receptor activity

  摘要：

  本申请描述了公式（I）的MCP-1调节剂或其药用盐形式，用于预防风湿性关节炎、多发性硬化症、动脉粥样硬化、哮喘、再狭窄、器官移植和癌症。

  公开号：

  US20030216434A1

文献信息

• Substituted cycloalkylamine derivatives as modulators of chemokine receptor activity
  申请人：Carter H. Percy

  公开号：US20050054626A1

  公开（公告）日：2005-03-10

  The present application describes modulators of MCP-1 of formula (I): or pharmaceutically acceptable salt forms thereof, useful for the prevention of asthma, multiple sclerosis, artherosclerosis, and rheumatoid arthritis.

  本申请描述了MCP-1的调节剂，化学式为(I)：或其药用可接受的盐形式，用于预防哮喘、多发性硬化症、动脉粥样硬化和类风湿性关节炎。
• Lactams of alkylated acyclic diamine derivatives as modulators of chemokine receptor activity
  申请人：Carter H. Percy

  公开号：US20050043392A1

  公开（公告）日：2005-02-24

  The present application describes modulators of MCP-1 of formula (I): or pharmaceutically acceptable salt forms thereof, useful for the prevention of asthma, multiple sclerosis, artherosclerosis, and rheumatoid arthritis.

  本申请描述了式(I)的MCP-1调节剂或其药用盐形式，可用于预防哮喘、多发性硬化症、动脉粥样硬化和类风湿性关节炎。
• Cyclic derivatives as modulators of chemokine receptors activity
  申请人：Cherney J. Robert

  公开号：US20060135503A1

  公开（公告）日：2006-06-22

  The present application describes modulators of MCP-1 of formula (I): or pharmaceutically acceptable salt forms thereof, useful for the prevention of rheumatoid arthritis, multiple sclerosis, atherosclerosis, asthma, restinosis, organ transplantation, and cancer.

  本申请描述了MCP-1调节剂的化学式(I)或其药学上可接受的盐形式，可用于预防类风湿性关节炎、多发性硬化症、动脉粥样硬化、哮喘、再狭窄、器官移植和癌症。
• Capped diaminopropionamide–glycine dipeptides are inhibitors of CC chemokine receptor 2 (CCR2)
  作者：Percy H. Carter、Gregory D. Brown、Sarah R. Friedrich、Robert J. Cherney、Andrew J. Tebben、Yvonne C. Lo、Gengjie Yang、Heather Jezak、Kimberly A. Solomon、Peggy A. Scherle、Carl P. Decicco

  DOI：10.1016/j.bmcl.2007.07.028

  日期：2007.10

  A new series of CCR2 antagonists has been discovered that incorporates intramolecular hydrogen bonding as a strategy for rigidifying the scaffold. The structure-activity relationship was established through initial systematic modification of substitution pattern and chain length, followed by independent optimization of three different substituents (benzylamine, carboxamide, and benzamide). Several of the acyclic compounds display 10-30 nM binding affinity for CCR2. Moreover, these antagonists are able to block both MCP-1-induced Ca2+ flux and monocyte chemotaxis, and are selective for binding to CCR2 over CCR1 and CCR3. (C) 2007 Elsevier Ltd. All rights reserved.
• CYCLIC DERIVATIVES AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY
  申请人：BRISTOL-MYERS SQUIBB COMPANY

  公开号：EP1343751A2

  公开（公告）日：2003-09-17